Program
Rifampin
Also written as “Rifampicin”, “rifampicin” and “RSS0343 Tablet; Rifampicin Capsules”.
Its studies are mostly in Neoplasms · Tuberculosis, Pulmonary · Hematologic Neoplasms · Melanoma · Bronchiectasis, led by 28 companies.
Drug pageRifampin: every studyMany companies study it; this page follows only the 45 they lead. All 162 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibbits history only | 40 open or running | phase 1since Sep 25, 2007 | Sep 25, 2007 | none ahead |
| AstraZenecaits history only | 30 open or running | phase 1since Aug 23, 2013 | Aug 23, 2013 | none ahead |
| HUTCHMEDits history only | 30 open or running | phase 1since Aug 10, 2020 | Aug 10, 2020 | none ahead |
| Jiangsu HengRui Medicineits history only | 32 open or running | phase 1since Jul 28, 2020 | Jul 28, 2020 | none ahead |
| Takedaits history only | 30 open or running | phase 1since Jan 23, 2008 | Jan 23, 2008 | none ahead |
| Boehringer Ingelheimits history only | 20 open or running | phase 1since Jun 20, 2014 | Jun 20, 2014 | none ahead |
| GlaxoSmithKlineits history only | 20 open or running | phase 2since May 16, 2022 | Sep 26, 2013 | none ahead |
| Hoffmann-La Rocheits history only | 20 open or running | phase 1since Jan 9, 2013 | Jan 9, 2013 | none ahead |
| Johnson & Johnsonits history only | 20 open or running | phase 1since Jan 23, 2012 | Jan 23, 2012 | none ahead |
| Pfizerits history only | 20 open or running | phase 1since Oct 3, 2006 | Oct 3, 2006 | none ahead |
| PTC Therapeuticsits history only | 20 open or running | phase 1since Nov 4, 2014 | Nov 4, 2014 | none ahead |
| Bayerits history only | 10 open or running | phase 1since Nov 4, 2016 | Nov 4, 2016 | none ahead |
| Beijing Aosaikang Pharmaceuticalits history only | 10 open or running | phase 1since Nov 11, 2022 | Nov 11, 2022 | none ahead |
| Betta Pharmaceuticalsits history only | 11 open or running | phase 1since Jul 1, 2024 | Jul 1, 2024 | none ahead |
| Eisaiits history only | 10 open or running | phase 1since Jan 23, 2014 | Jan 23, 2014 | none ahead |
| Emalex Biosciencesits history only | 10 open or running | phase 1since Dec 22, 2023 | Dec 22, 2023 | none ahead |
| F2G Biotechits history only | 10 open or running | phase 1since Nov 19, 2019 | Nov 19, 2019 | none ahead |
| Guangdong Zhongsheng Pharmaceuticalits history only | 10 open or running | phase 1since Sep 4, 2023 | Sep 4, 2023 | none ahead |
| Idorsia Pharmaceuticalsits history only | 10 open or running | phase 1since Jul 5, 2018 | Jul 5, 2018 | none ahead |
| Ipsenits history only | 10 open or running | phase 1since Jul 29, 2020 | Jul 29, 2020 | none ahead |
| LG Chemits history only | 10 open or running | phase 1since Aug 31, 2011 | Aug 31, 2011 | none ahead |
| Phathom Pharmaceuticalsits history only | 10 open or running | phase 1since Sep 15, 2020 | Sep 15, 2020 | none ahead |
| SecuraBioits history only | 10 open or running | phase 1since Sep 18, 2013 | Sep 18, 2013 | none ahead |
| Sunshine Lake Pharmaits history only | 10 open or running | phase 1since Aug 31, 2021 | Aug 31, 2021 | none ahead |
| Thirty Respiratoryits history only | 10 open or running | phase 2since Aug 21, 2023 | Aug 21, 2023 | none ahead |
| TYK Medicinesits history only | 10 open or running | phase 1since Jan 17, 2024 | Jan 17, 2024 | none ahead |
| Vantiaits history only | 10 open or running | phase 1since May 7, 2015 | May 7, 2015 | none ahead |
| Vertex Pharmaceuticalsits history only | 10 open or running | phase 1since Nov 19, 2009 | Nov 19, 2009 | none ahead |
Also a collaborator on its studies: Cambridge Cognition, Parexel, Covance and PRA Health Sciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 31 studies since Oct 3, 2006.
- Sep 15, 2020Phase 1 study in Drug Drug InteractionHUTCHMED · NCT04557397 · 28 enrolled · United States
- Jun 8, 2021Phase 1 study in Advanced Solid TumoursAstraZeneca · NCT04959266 · 5 enrolled · United States, Spain
- Aug 31, 2021Sunshine Lake Pharma’s first study: phase 1 study in Healthy VolunteersNew to Sunshine Lake PharmaSunshine Lake Pharma · NCT05057949 · 32 enrolled · China
- Feb 10, 2022Phase 1 study in Healthy AdultsBristol-Myers Squibb · NCT05255276 · 36 enrolled · United States
- May 16, 2022Phase 2 study in TuberculosisGlaxoSmithKline · NCT05382312 · 127 enrolled · South Africa
- Oct 27, 2022Phase 1 study in RecurrenceHUTCHMED · NCT05602597 · 59 enrolled · United States
- Nov 11, 2022Beijing Aosaikang Pharmaceutical’s first study: phase 1 study in Carcinoma, Non-Small-Cell LungNew to Beijing Aosaikang PharmaceuticalBeijing Aosaikang Pharmaceutical · NCT05631678 · 48 enrolled · China
- Aug 21, 2023Thirty Respiratory’s first study: phase 2 study in Rifampicin Susceptible Pulmonary TuberculosisNew to Thirty RespiratoryThirty Respiratory · NCT06041919 · 20 enrolled · South Africa
- Sep 4, 2023Guangdong Zhongsheng Pharmaceutical’s first study: phase 1 study in Drug Drug InteractionNew to Guangdong Zhongsheng PharmaceuticalGuangdong Zhongsheng Pharmaceutical · NCT06031454 · 56 enrolled · China
- Dec 22, 2023Emalex Biosciences’ first study: phase 1 study in Drug InteractionNew to Emalex BiosciencesEmalex Biosciences · NCT06194864 · 45 enrolled · Canada
- Jan 17, 2024TYK Medicines’ first study: phase 1 study in NSCLCNew to TYK MedicinesTYK Medicines · NCT06255951 · 48 enrolled · China
- Mar 22, 2024Phase 1 study in Renal Insufficiency, ChronicJiangsu HengRui Medicine · NCT06344936 · 28 planned · China
- Jul 1, 2024Betta Pharmaceuticals’ first study: phase 1 study in HealthyNew to Betta PharmaceuticalsBetta Pharmaceuticals · NCT06492525 · 36 planned · China
- Jul 6, 2026Phase 1 study in Non-cystic Fibrosis Bronchiectasis、Chronic Sinusitis Without Nasal Polyps、Chronic Obstructive Pulmonary DiseaseJiangsu HengRui Medicine · NCT07696091 · 40 planned · China
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Bacterial DNA-directed RNA polymerase inhibitor”ChEMBL 37, by rule
Studies
All 45 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07696091Non-cystic Fibrosis Bronchiectasis、Chronic Sinusitis Without Nasal Polyps、Chronic Obstructive Pulmonary Disease · China | 1 | Not yet recruiting | Jiangsu HengRui Medicine | Sep 2026 | 40 |
| NCT06492525Healthy · China | 1 | Not yet recruiting | Betta Pharmaceuticals | Oct 2024 | 36 |
| NCT06344936Renal Insufficiency, Chronic · China | 1 | Not yet recruiting | Jiangsu HengRui Medicine | Jul 2024 | 28 |
| NCT06255951NSCLC · China | 1 | Completed | TYK Medicines | May 23, 2024 | 48 |
| NCT06194864Drug Interaction · Canada | 1 | Completed | Emalex Biosciences | May 14, 2024 | 45 |
| NCT06031454Drug Drug Interaction · China | 1 | Completed | Guangdong Zhongsheng Pharmaceutical | Nov 1, 2023 | 56 |
| NCT06041919Rifampicin Susceptible Pulmonary Tuberculosis · South Africa | 2 | Terminated | Thirty Respiratory | Jul 24, 2024 | 20 |
| NCT05631678Carcinoma, Non-Small-Cell Lung · China | 1 | Completed | Beijing Aosaikang Pharmaceutical | Aug 3, 2022 | 48 |
| NCT05602597Recurrence · United States | 1 | Completed | HUTCHMED | Aug 6, 2022 | 59 |
| NCT05382312Tuberculosis · South Africa | 2 | Completed | GlaxoSmithKline | May 27, 2025 | 127 |
| NCT05255276Healthy Adults · United States | 1 | Completed | Bristol-Myers Squibb | May 12, 2022 | 36 |
| NCT05057949Healthy Volunteers · China | 1 | Completed | Sunshine Lake Pharma | Feb 17, 2022 | 32 |
| NCT04959266Advanced Solid Tumours · United States, Spain | 1 | Terminated | AstraZeneca | Jun 1, 2022 | 5 |
| NCT04558216Healthy Participants · United States | 1 | Withdrawn | Phathom Pharmaceuticals | Feb 7, 2021 | 0 |
| NCT04557397Drug Drug Interaction · United States | 1 | Completed | HUTCHMED | Oct 18, 2020 | 28 |
| NCT04510649Healthy · United States | 1 | Completed | HUTCHMED | Sep 11, 2020 | 28 |
| NCT04537715Hematologic Neoplasms · United States, Spain | 1 | Completed | Ipsen | Apr 3, 2023 | 42 |
| NCT04494659Healthy Adult Subjects · China | 1 | Completed | Jiangsu HengRui Medicine | Aug 13, 2020 | 21 |
| NCT04171739Healthy · United Kingdom | 1 | Completed | F2G Biotech | Feb 11, 2020 | 24 |
| NCT03596294Healthy Subjects · Netherlands | 1 | Completed | Idorsia Pharmaceuticals | Aug 3, 2018 | 14 |
| NCT03486314Advanced Solid Neoplasm · United States | 1 | Completed | Takeda | May 10, 2019 | 20 |
| NCT03307252Healthy · Germany | 1 | Completed | Boehringer Ingelheim | May 2, 2018 | 45 |
| NCT02975440Endometriosis · Germany | 1 | Completed | Bayer | Jan 27, 2017 | 12 |
| NCT02770222Healthy Subjects | 1 | Completed | Johnson & Johnson | Jul 2016 | 40 |
| NCT02608034Melanoma · United States, Israel, Korea, Republic of and more | 1 | Completed | Hoffmann-La Roche | Sep 10, 2018 | 32 |
| NCT02440841Nocturia · Germany | 1 | Completed | Vantia | Jul 2015 | 29 |
| NCT02409004Healthy · Canada | 1 | Completed | PTC Therapeutics | Mar 2015 | 15 |
| NCT02286635Healthy Volunteers · United States | 1 | Completed | PTC Therapeutics | Dec 2014 | 58 |
| NCT02173717Healthy | 1 | Completed | Boehringer Ingelheim | Jul 2009 | 24 |
| NCT02046850Solid Tumours · United States | 1 | Completed | AstraZeneca | Apr 2014 | 24 |
| NCT02055703Healthy Subjects · United States | 1 | Completed | Eisai | Apr 2014 | 195 |
| NCT01954043Neoplasms · United States, Australia, United Kingdom | 1 | Completed | GlaxoSmithKline | Feb 29, 2016 | 23 |
| NCT01950364Hodgkin Disease · Belgium, Lithuania, Spain | 1 | Completed | Takeda | Oct 2014 | 20 |
| NCT01947777Healthy · United States | 1 | Completed | SecuraBio | Nov 2013 | 14 |
| NCT01929603Neoplasms · Belgium, Netherlands | 1 | Completed | AstraZeneca | May 2014 | 32 |
| NCT01765543Melanoma · United States, Brazil, Croatia and more | 1 | Completed | Hoffmann-La Roche | Nov 2015 | 27 |
| NCT01655147Healthy · Belgium | 1 | Completed | Johnson & Johnson | Mar 2012 | 19 |
| NCT01426906Healthy Male Volunteers · Korea, Republic of | 1 | Completed | LG Chem | Mar 2011 | 24 |
| NCT01324323Hematologic Neoplasms · United States, United Kingdom | 1 | Completed | Bristol-Myers Squibb | Feb 1, 2012 | 14 |
| NCT01311505Tuberculosis · Philippines | 1 | Completed | Pfizer | May 2011 | 21 |
| NCT01018368Cystic Fibrosis · United States | 1 | Completed | Vertex Pharmaceuticals | Mar 2010 | 24 |
| NCT01002079Alzheimer Disease · India | 1 | Completed | Bristol-Myers Squibb | Oct 2010 | 20 |
| NCT00608907Multiple Myeloma · Israel, Italy, Poland and more | 1 | Completed | Takeda | Mar 2010 | 61 |
| NCT00534807Neoplasms · United States | 1 | Withdrawn | Bristol-Myers Squibb | Nov 2008 | 0 |
| NCT00384280Healthy | 1 | Completed | Pfizer | Nov 2006 | 24 |
How it is read
Names in the registry
- “Rifampin”, 18 entries
- “Rifampicin”, 9 entries
- “rifampicin”, 5 entries
- “RSS0343 Tablet; Rifampicin Capsules”, 1 entry
- “RIFAFOUR e-275”, 1 entry
Conditions, from the studies’ own filings
- Neoplasms, 3 studies
- Tuberculosis, Pulmonary, 2 studies
- Hematologic Neoplasms, 2 studies
- Melanoma, 2 studies
- Bronchiectasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.